Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2016 Jan;14(1):19-30.
doi: 10.6004/jnccn.2016.0004.

Prostate Cancer, Version 1.2016

James L Mohler  1 , Andrew J Armstrong  2 , Robert R Bahnson  3 , Anthony Victor D'Amico  4 , Brian J Davis  5 , James A Eastham  6 , Charles A Enke  7 , Thomas A Farrington  8 , Celestia S Higano  9 , Eric M Horwitz  10 , Michael Hurwitz  11 , Christopher J Kane  12 , Mark H Kawachi  13 , Michael Kuettel  1 , Richard J Lee  14 , Joshua J Meeks  15 , David F Penson  16 , Elizabeth R Plimack  17 , Julio M Pow-Sang  18 , David Raben  19 , Sylvia Richey  20 , Mack Roach 3rd  21 , Stan Rosenfeld  22 , Edward Schaeffer  23 , Ted A Skolarus  20 , Eric J Small  24 , Guru Sonpavde  25 , Sandy Srinivas  26 , Seth A Strope  26 , Jonathan Tward  27 , Dorothy A Shead  28 , Deborah A Freedman-Cass  28
Affiliations
Practice Guideline

Prostate Cancer, Version 1.2016

James L Mohler et al. J Natl Compr Canc Netw. 2016 Jan.

Abstract

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.

PubMed Disclaimer

Comment in

  • Editorial Comment.
    Tosoian JJ, Alam R, Carter HB. Tosoian JJ, et al. J Urol. 2016 Dec;196(6):1658. doi: 10.1016/j.juro.2016.06.105. Epub 2016 Sep 15. J Urol. 2016. PMID: 27639611 No abstract available.

Similar articles

  • NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.
    Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, D'Amico AV, Davis BJ, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Horwitz EM, Ippolito JE, Kuettel MR, Lang JM, McKay R, McKenney J, Netto G, Penson DF, Pow-Sang JM, Reiter R, Richey S, Roach Iii M, Rosenfeld S, Shabsigh A, Spratt DE, Teply BA, Tward J, Shead DA, Freedman-Cass DA. Schaeffer E, et al. J Natl Compr Canc Netw. 2021 Feb 2;19(2):134-143. doi: 10.6004/jnccn.2021.0008. J Natl Compr Canc Netw. 2021. PMID: 33545689
  • NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
    Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA, Freedman-Cass DA. Schaeffer EM, et al. J Natl Compr Canc Netw. 2022 Dec;20(12):1288-1298. doi: 10.6004/jnccn.2022.0063. J Natl Compr Canc Netw. 2022. PMID: 36509074
  • NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024.
    Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Karnes RJ, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Szmulewitz R, Teply BA, Tward J, Valicenti R, Wong JK, Snedeker J, Freedman-Cass DA. Schaeffer EM, et al. J Natl Compr Canc Netw. 2024 Apr;22(3):140-150. doi: 10.6004/jnccn.2024.0019. J Natl Compr Canc Netw. 2024. PMID: 38626801
  • Screening, risk assessment, and the approach to therapy in patients with prostate cancer.
    Freedland SJ. Freedland SJ. Cancer. 2011 Mar 15;117(6):1123-35. doi: 10.1002/cncr.25477. Epub 2010 Oct 19. Cancer. 2011. PMID: 20960523 Review.
  • Epidemiology, diagnosis and treatment of prostate cancer.
    Newman J. Newman J. Radiol Technol. 1996 Sep-Oct;68(1):39-64; quiz 65-8. Radiol Technol. 1996. PMID: 8880970 Review.
See all similar articles

Cited by

See all "Cited by" articles

Publication types